ArticleNature communications2017
Covalent assembly of nanoparticles as a peptidase-degradable platform for molecular MRI.
Article in Nature communications, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed.
- A review of preparation methods and biomedical applications of micro-nano magnetic particles.iScience · 2026Review
- In Vivo PET Detection of Lung Micrometastasis in Mice by Targeting Endothelial VCAM-1 Using a Dual-Contrast PET/MRI Probe.International journal of molecular sciences · 2024Article
- MRI-based microthrombi detection in stroke with polydopamine iron oxide.Nature communications · 2024Article
- MicroRNAs as regulators of immune checkpoints in cancer immunotherapy: targeting PD-1/PD-L1 and CTLA-4 pathways.Cancer cell international · 2024Review
- In vivo methods for imaging blood-brain barrier function and dysfunction.European journal of nuclear medicine and molecular imaging · 2023Review
- Strategies targeting PD-L1 expression and associated opportunities for cancer combination therapy.Theranostics · 2023Review
- MRI techniques for immunotherapy monitoring.Journal for immunotherapy of cancer · 2022Review
- Tracking the immune response by MRI using biodegradable and ultrasensitive microprobes.Science advances · 2022Article
- Micro/Nanosystems for Magnetic Targeted Delivery of Bioagents.Pharmaceutics · 2022Review
- Bioinspired Magnetic Nanochains for Medicine.Pharmaceutics · 2021Review
- A novel molecular magnetic resonance imaging agent targeting activated leukocyte cell adhesion molecule as demonstrated in mouse brain metastasis models.Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2021Article
- Imaging Extracellular Acidification and Immune Activation in Cancer.Current opinion in biomedical engineering · 2021Article
- New Approaches in Nanomedicine for Ischemic Stroke.Pharmaceutics · 2021Review
- Rational Design of All-Organic Nanoplatform for Highly Efficient MR/NIR-II Imaging-Guided Cancer Phototheranostics.Small (Weinheim an der Bergstrasse, Germany) · 2021Article
- Design and Preparation of "corn-like" SPIONs@DFK-SBP-M13 Assembly for Improvement of Effective Internalization.International journal of nanomedicine · 2021Article
- Cardiovascular magnetic resonance imaging for inflammatory heart diseases.Cardiovascular diagnosis and therapy · 2020Review
- Magnetic Nanoparticles as MRI Contrast Agents.Topics in current chemistry (Cham) · 2020Review
- Improving Delineation of True Tumor Volume With Multimodal MRI in a Rat Model of Brain Metastasis.International journal of radiation oncology, biology, physics · 2020Article
- Improved detection of molecularly targeted iron oxide particles in mouse brain using BMagnetic resonance imaging · 2020Article
- Inhibition of Immunosuppressive Tumors by Polymer-Assisted Inductions of Immunogenic Cell Death and Multivalent PD-L1 Crosslinking.Advanced functional materials · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
Abstract
Ligand-conjugated microparticles of iron oxide (MPIO) have the potential to provide high sensitivity contrast for molecular magnetic resonance imaging (MRI). However, the accumulation and persistence of non-biodegradable micron-sized particles in liver and spleen precludes their clinical use and limits the translational potential of MPIO-based contrast agents. Here we show that ligand-targeted MPIO derived from multiple iron oxide nanoparticles may be coupled covalently through peptide linkers that are designed to be cleaved by intracellular macrophage proteases. The synthesized particles possess potential characteristics for targeted MRI contrast agents, including high relaxivity, unappreciable sedimentation, clearance from circulation and no overt toxicity. Importantly, we demonstrate that these particles are rapidly degraded both in vitro and in vivo, and that the targeted probes can be used for detection of inflammation in vivo using MRI. This approach provides a platform for molecular MRI contrast agents that is potentially more suitable for translation to humans.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.